Selected research
Market Structure
Global Non-iodinated X-ray Contrast Agents Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032
Market perspective
The global Non-iodinated X-ray Contrast Agents market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.
The US & Canada market for Non-iodinated X-ray Contrast Agents is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
The Europe market for Non-iodinated X-ray Contrast Agents is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Read the full market overview
The Asia Pacific market for Non-iodinated X-ray Contrast Agents is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
The China market for Non-iodinated X-ray Contrast Agents is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Leading global manufacturers of Non-iodinated X-ray Contrast Agents include Bracco Diagnostics, Guerbet Group, Qinhuangdao Zizhu Pharmaceutical Co., Ltd., Qingdao Hongdie New Materials Co., Ltd., Shandong Shengli Pharmaceutical Co., Ltd., Taishan Xinning Pharmaceutical Co., Ltd. and Xi'an Disai Biopharmaceutical Co., Ltd., among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
This report provides an overview of the global Non-iodinated X-ray Contrast Agents market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.
The study covers key producers of Non-iodinated X-ray Contrast Agents and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.
The report also presents Non-iodinated X-ray Contrast Agents sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.
In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Non-iodinated X-ray Contrast Agents market size, projected growth trends, production technologies, key applications, and end-use industries.
Non-iodinated X-ray Contrast Agents Segment by Company
Bracco Diagnostics
Guerbet Group
Qinhuangdao Zizhu Pharmaceutical Co., Ltd.
Qingdao Hongdie New Materials Co., Ltd.
Shandong Shengli Pharmaceutical Co., Ltd.
Taishan Xinning Pharmaceutical Co., Ltd.
Xi'an Disai Biopharmaceutical Co., Ltd.
Non-iodinated X-ray Contrast Agents Segment by Type
Barium Sulfate Type I
Barium Sulfate Type II
Non-iodinated X-ray Contrast Agents Segment by Application
Hospital
Clinic
Other
Non-iodinated X-ray Contrast Agents Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Study Objectives
1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Non-iodinated X-ray Contrast Agents market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Non-iodinated X-ray Contrast Agents and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Non-iodinated X-ray Contrast Agents.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Provides an overview of the Non-iodinated X-ray Contrast Agents market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).
Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Non-iodinated X-ray Contrast Agents manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Non-iodinated X-ray Contrast Agents in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Revenue of Non-iodinated X-ray Contrast Agents in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Concluding Insights of the report
More report detail
Tables and figures
Scope & coverage.
Types
- Barium Sulfate Type I
- Barium Sulfate Type II
Applications
- Hospital
- Clinic
- Other
Companies covered
- Bracco Diagnostics
- Guerbet Group
- Qinhuangdao Zizhu Pharmaceutical Co., Ltd.
- Qingdao Hongdie New Materials Co., Ltd.
- Shandong Shengli Pharmaceutical Co., Ltd.
- Taishan Xinning Pharmaceutical Co., Ltd.
- Xi'an Disai Biopharmaceutical Co., Ltd.
Inside the report.
1 Market Overview
- 1.1 Product Definition
- 1.2 Global Non-iodinated X-ray Contrast Agents Market Size, 2021 VS 2025 VS 2032
- 1.3 Global Non-iodinated X-ray Contrast Agents Market Size Estimates and Forecasts (2021-2032)
- 1.4 Global Non-iodinated X-ray Contrast Agents Sales Estimates and Forecasts (2021-2032)
- 1.5 Global Non-iodinated X-ray Contrast Agents Market Average Price (2021-2032)
- 1.6 Assumptions and Limitations
- 1.7 Study Goals and Objectives
2 Global Non-iodinated X-ray Contrast Agents Market Dynamics
- 2.1 Non-iodinated X-ray Contrast Agents Industry Trends
- 2.2 Non-iodinated X-ray Contrast Agents Industry Drivers
- 2.3 Non-iodinated X-ray Contrast Agents Industry Opportunities and Challenges
- 2.4 Non-iodinated X-ray Contrast Agents Industry Restraints
3 Non-iodinated X-ray Contrast Agents Market by Manufacturers
- 3.1 Global Non-iodinated X-ray Contrast Agents Revenue by Manufacturers (2021-2026)
- 3.2 Global Non-iodinated X-ray Contrast Agents Sales by Manufacturers (2021-2026)
- 3.3 Global Non-iodinated X-ray Contrast Agents Average Sales Price by Manufacturers (2021-2026)
- 3.4 Global Non-iodinated X-ray Contrast Agents Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
- 3.5 Global Non-iodinated X-ray Contrast Agents Key Manufacturers Manufacturing Sites & Headquarters
- 3.6 Global Non-iodinated X-ray Contrast Agents Manufacturers, Product Type & Application
- 3.7 Global Non-iodinated X-ray Contrast Agents Manufacturers Establishment Date
- 3.8 Market Competitive Analysis
- 3.8.1 Global Non-iodinated X-ray Contrast Agents Market CR5 and HHI
- 3.8.2 Global Top 5 and 10 Non-iodinated X-ray Contrast Agents Players Market Share by Revenue in 2025
- 3.8.3 2025 Non-iodinated X-ray Contrast Agents Tier 1, Tier 2, and Tier 3
4 Non-iodinated X-ray Contrast Agents Market by Type
- 4.1 Non-iodinated X-ray Contrast Agents Type Introduction
- 4.1.1 Barium Sulfate Type I
- 4.1.2 Barium Sulfate Type II
- 4.2 Global Non-iodinated X-ray Contrast Agents Sales by Type
- 4.2.1 Global Non-iodinated X-ray Contrast Agents Sales by Type (2021 VS 2025 VS 2032)
- 4.2.2 Global Non-iodinated X-ray Contrast Agents Sales by Type (2021-2032)
- 4.2.3 Global Non-iodinated X-ray Contrast Agents Sales Market Share by Type (2021-2032)
- 4.3 Global Non-iodinated X-ray Contrast Agents Revenue by Type
- 4.3.1 Global Non-iodinated X-ray Contrast Agents Revenue by Type (2021 VS 2025 VS 2032)
- 4.3.2 Global Non-iodinated X-ray Contrast Agents Revenue by Type (2021-2032)
- 4.3.3 Global Non-iodinated X-ray Contrast Agents Revenue Market Share by Type (2021-2032)
5 Non-iodinated X-ray Contrast Agents Market by Application
- 5.1 Non-iodinated X-ray Contrast Agents Application Introduction
- 5.1.1 Hospital
- 5.1.2 Clinic
- 5.1.3 Other
- 5.2 Global Non-iodinated X-ray Contrast Agents Sales by Application
- 5.2.1 Global Non-iodinated X-ray Contrast Agents Sales by Application (2021 VS 2025 VS 2032)
- 5.2.2 Global Non-iodinated X-ray Contrast Agents Sales by Application (2021-2032)
- 5.2.3 Global Non-iodinated X-ray Contrast Agents Sales Market Share by Application (2021-2032)
- 5.3 Global Non-iodinated X-ray Contrast Agents Revenue by Application
- 5.3.1 Global Non-iodinated X-ray Contrast Agents Revenue by Application (2021 VS 2025 VS 2032)
- 5.3.2 Global Non-iodinated X-ray Contrast Agents Revenue by Application (2021-2032)
- 5.3.3 Global Non-iodinated X-ray Contrast Agents Revenue Market Share by Application (2021-2032)
6 Global Non-iodinated X-ray Contrast Agents Sales by Region
- 6.1 Global Non-iodinated X-ray Contrast Agents Sales by Region: 2021 VS 2025 VS 2032
- 6.2 Global Non-iodinated X-ray Contrast Agents Sales by Region (2021-2032)
- 6.2.1 Global Non-iodinated X-ray Contrast Agents Sales by Region (2021-2026)
- 6.2.2 Global Non-iodinated X-ray Contrast Agents Sales Forecasted by Region (2027-2032)
- 6.3 North America
- 6.3.1 North America Non-iodinated X-ray Contrast Agents Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.3.2 North America Non-iodinated X-ray Contrast Agents Sales by Country (2021-2032)
- 6.3.3 U.S.
- 6.3.4 Canada
- 6.3.5 Mexico
- 6.4 Europe
- 6.4.1 Europe Non-iodinated X-ray Contrast Agents Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.4.2 Europe Non-iodinated X-ray Contrast Agents Sales by Country (2021-2032)
- 6.4.3 Germany
- 6.4.4 France
- 6.4.5 U.K.
- 6.4.6 Italy
- 6.4.7 Netherlands
- 6.5 Asia Pacific
- 6.5.1 Asia Pacific Non-iodinated X-ray Contrast Agents Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.5.2 Asia Pacific Non-iodinated X-ray Contrast Agents Sales by Country (2021-2032)
- 6.5.3 China
- 6.5.4 Japan
- 6.5.5 South Korea
- 6.5.6 Southeast Asia
- 6.5.7 India
- 6.5.8 Australia
- 6.6 South America, Middle East and Africa
- 6.6.1 South America, Middle East and Africa Non-iodinated X-ray Contrast Agents Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.6.2 South America, Middle East and Africa Non-iodinated X-ray Contrast Agents Sales by Country (2021-2032)
- 6.6.3 Brazil
- 6.6.4 South Africa
- 6.6.5 Saudi Arabia
- 6.6.6 Turkey
- 6.6.6 Argentina
- 6.6.6 UAE
- 6.6.6 Egypt
- 6.6.6 Chile
7 Global Non-iodinated X-ray Contrast Agents Revenue by Region
- 7.1 Global Non-iodinated X-ray Contrast Agents Revenue by Region
- 7.1.1 Global Non-iodinated X-ray Contrast Agents Revenue by Region: 2021 VS 2025 VS 2032
- 7.1.2 Global Non-iodinated X-ray Contrast Agents Revenue by Region (2021-2026)
- 7.1.3 Global Non-iodinated X-ray Contrast Agents Revenue by Region (2027-2032)
- 7.1.4 Global Non-iodinated X-ray Contrast Agents Revenue Market Share by Region (2021-2032)
- 7.2 North America
- 7.2.1 North America Non-iodinated X-ray Contrast Agents Revenue (2021-2032)
- 7.2.2 North America Non-iodinated X-ray Contrast Agents Revenue Share by Country: 2021 VS 2025 VS 2032
- 7.3 Europe
- 7.3.1 Europe Non-iodinated X-ray Contrast Agents Revenue (2021-2032)
- 7.3.2 Europe Non-iodinated X-ray Contrast Agents Revenue Share by Country: 2021 VS 2025 VS 2032
- 7.4 Asia-Pacific
- 7.4.1 Asia-Pacific Non-iodinated X-ray Contrast Agents Revenue (2021-2032)
- 7.4.2 Asia-Pacific Non-iodinated X-ray Contrast Agents Revenue Share by Country: 2021 VS 2025 VS 2032
- 7.5 South America, Middle East and Africa
- 7.5.1 South America, Middle East and Africa Non-iodinated X-ray Contrast Agents Revenue (2021-2032)
- 7.5.2 South America, Middle East and Africa Non-iodinated X-ray Contrast Agents Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
- 8.1 Bracco Diagnostics
- 8.1.1 Bracco Diagnostics Company Information
- 8.1.2 Bracco Diagnostics Business Overview
- 8.1.3 Bracco Diagnostics Non-iodinated X-ray Contrast Agents Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.1.4 Bracco Diagnostics Non-iodinated X-ray Contrast Agents Product Portfolio
- 8.1.5 Bracco Diagnostics Recent Developments
- 8.2 Guerbet Group
- 8.2.1 Guerbet Group Company Information
- 8.2.2 Guerbet Group Business Overview
- 8.2.3 Guerbet Group Non-iodinated X-ray Contrast Agents Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.2.4 Guerbet Group Non-iodinated X-ray Contrast Agents Product Portfolio
- 8.2.5 Guerbet Group Recent Developments
- 8.3 Qinhuangdao Zizhu Pharmaceutical Co., Ltd.
- 8.3.1 Qinhuangdao Zizhu Pharmaceutical Co., Ltd. Company Information
- 8.3.2 Qinhuangdao Zizhu Pharmaceutical Co., Ltd. Business Overview
- 8.3.3 Qinhuangdao Zizhu Pharmaceutical Co., Ltd. Non-iodinated X-ray Contrast Agents Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.3.4 Qinhuangdao Zizhu Pharmaceutical Co., Ltd. Non-iodinated X-ray Contrast Agents Product Portfolio
- 8.3.5 Qinhuangdao Zizhu Pharmaceutical Co., Ltd. Recent Developments
- 8.4 Qingdao Hongdie New Materials Co., Ltd.
- 8.4.1 Qingdao Hongdie New Materials Co., Ltd. Company Information
- 8.4.2 Qingdao Hongdie New Materials Co., Ltd. Business Overview
- 8.4.3 Qingdao Hongdie New Materials Co., Ltd. Non-iodinated X-ray Contrast Agents Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.4.4 Qingdao Hongdie New Materials Co., Ltd. Non-iodinated X-ray Contrast Agents Product Portfolio
- 8.4.5 Qingdao Hongdie New Materials Co., Ltd. Recent Developments
- 8.5 Shandong Shengli Pharmaceutical Co., Ltd.
- 8.5.1 Shandong Shengli Pharmaceutical Co., Ltd. Company Information
- 8.5.2 Shandong Shengli Pharmaceutical Co., Ltd. Business Overview
- 8.5.3 Shandong Shengli Pharmaceutical Co., Ltd. Non-iodinated X-ray Contrast Agents Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.5.4 Shandong Shengli Pharmaceutical Co., Ltd. Non-iodinated X-ray Contrast Agents Product Portfolio
- 8.5.5 Shandong Shengli Pharmaceutical Co., Ltd. Recent Developments
- 8.6 Taishan Xinning Pharmaceutical Co., Ltd.
- 8.6.1 Taishan Xinning Pharmaceutical Co., Ltd. Company Information
- 8.6.2 Taishan Xinning Pharmaceutical Co., Ltd. Business Overview
- 8.6.3 Taishan Xinning Pharmaceutical Co., Ltd. Non-iodinated X-ray Contrast Agents Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.6.4 Taishan Xinning Pharmaceutical Co., Ltd. Non-iodinated X-ray Contrast Agents Product Portfolio
- 8.6.5 Taishan Xinning Pharmaceutical Co., Ltd. Recent Developments
- 8.7 Xi'an Disai Biopharmaceutical Co., Ltd.
- 8.7.1 Xi'an Disai Biopharmaceutical Co., Ltd. Company Information
- 8.7.2 Xi'an Disai Biopharmaceutical Co., Ltd. Business Overview
- 8.7.3 Xi'an Disai Biopharmaceutical Co., Ltd. Non-iodinated X-ray Contrast Agents Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.7.4 Xi'an Disai Biopharmaceutical Co., Ltd. Non-iodinated X-ray Contrast Agents Product Portfolio
- 8.7.5 Xi'an Disai Biopharmaceutical Co., Ltd. Recent Developments
9 Value Chain and Sales Channels Analysis
- 9.1 Non-iodinated X-ray Contrast Agents Value Chain Analysis
- 9.1.1 Non-iodinated X-ray Contrast Agents Key Raw Materials
- 9.1.2 Raw Materials Key Suppliers
- 9.1.3 Manufacturing Cost Structure
- 9.1.4 Non-iodinated X-ray Contrast Agents Production Mode & Process
- 9.2 Non-iodinated X-ray Contrast Agents Sales Channels Analysis
- 9.2.1 Direct Comparison with Distribution Share
- 9.2.2 Non-iodinated X-ray Contrast Agents Distributors
- 9.2.3 Non-iodinated X-ray Contrast Agents Customers
10 Concluding Insights
11 Appendix
- 11.1 Reasons for Doing This Study
- 11.2 Research Methodology
- 11.3 Research Process
- 11.4 Authors List of This Report
- 11.5 Data Source
- 11.5.1 Secondary Sources
- 11.5.2 Primary Sources
- 11.6 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst